Crossmark

Targeting RSK2 enhances the efficacy of IGF1R inhibitor against triple-negative breast cancer via antagonizing IGF1/IGF1R signaling mediated by GATA3-IGFBP5 pathway

Crossref DOI link: https://doi.org/10.1038/s41401-025-01673-w

Published Online: 2026-01-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shan, Tian-jiao

Li, Lan-ya

Wan, Xiao-ya

Li, Yi-zhi

Jiang, Ting

Chen, Zong-lin

Yu, Xiao-hui

Cheng, Yan
License Information

Text and Data Mining valid from 2026-01-07

Version of Record valid from 2026-01-07
More Information

Article History

Received: 2 June 2025

Accepted: 11 September 2025

First Online: 7 January 2026

Competing interests

: The authors declare no competing interests.

: The animal protocol adhered to the institutional guidelines of the Animal Care and Use Committee of Central South University. Breast cancer tissues were obtained from The Second Xiangya Hospital, Central South University (Changsha, China). This study conformed to clinical research guidelines and was approved by the research ethics committee of The Second Xiangya Hospital. Written informed consent was obtained from all patients.

Document is current

Any future updates will be listed below